Cell culture media development and manufacturing specialist Irvine Scientific has established a new agreement with Corning Incorporated giving Irvine Scientific US distribution rights for Corning’s Falcon range of IVF dishes and plates. All Falcon IVF plasticware is manufactured from crystalline polystyrene, which is tested for USP Class VI cytotoxicity and is highly suited for applications such as oocyte preparation, fertilisation, culture and transfer. The range meets applicable FDA regulatory compliance, quality assurance and 510 (K) requirements.
For further information about Irvine Scientific's IVF technology and products visit www.irvinesci.com/assisted-reproductive-technology
- Leading cell culture media company changes name to FUJIFILM Irvine Scientific, Inc
- Irvine Scientific introduces chemically-defined natural killer cell expansion medium for immunotherapy and translational research applications
- JXTG Energy sells Irvine Scientific to FujiFilm
- Irvine Scientific increases cell culture dry powder media production capacity
- Irvine Scientific opens new R&D centre in Orange County, California
- Irvine Scientific introduces new xeno-free hematopoietic progenitor cell culture medium
- Charles River Laboratories expands oncology business
- Irvine Scientific develops novel bioassay for IVF components and media
- Irvine Scientific introduces animal-component-free T-cell culture medium for immunotherapy applications
Latest from Tom Mulligan
- EVENT PREVIEW: CPhI North America opens next week!
- NEW BUSINESS: SK biotek and AMPAC Fine Chemicals have ambitious CDMO plans
- NEW TECHNOLOGY: Polyplus-transfection develops GMP-grade therapeutic virus reagent
- Mogrify raises $3.7 million seed funding to support direct cellular conversion for cell therapy
- Owlstone Medical partners with Shanghai Renji Hospital to pioneer Breath Biopsy lung cancer trial
- Chemspace and LabNetwork collaborate to extend access to chemical databases
- TECHNOLOGY UPDATE: Catalent invests over $27 million to commercialise next-generation ODT Zydis Ultra
- SGS reports successful Phase 2 results for novel influenza vaccine, validating its H3N2 A/Belgium challenge agent
- NEW TECHNOLOGY: Horizon Discovery and Rutgers University develop new gene editing approach: ‘base editing’
- EVENT REVIEW: Busy sessions at BIO-Europe Spring!